Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruzinurad + Febuxostat in Gout with Inadequate Response
NCT05513976Phase 2Unknown
- Sponsor
- Hengrui
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ruzinurad in primary gout, hyperuricemia, sponsored by Hengrui. Status: unknown.
02
Drugs
ruzinurad
03
Conditions
primary gouthyperuricemia
Beyond the preview
Go deeper on NCT05513976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513976.